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Olsen and Harlan Anderson were working at Massachusetts Institute of Technology and noticed that students would line up for hours waiting for interactive terminals. They built Digital Equipment Corporation based upon this concept of interactive behavior between users and computer and created a powerhouse that in 30 yrs became the second largest computer company, threatening the hegemony of IBM (1957Y2002). Digital Equipment Corporation continued to pay close attention to the customer as it developed the programmable data processor family and the virtual access extension mini-computer. After several market research studies, its founder, Ken Olsen, famously stated his opinion about personal computers in 1977 that Bthere is no reason for any individual to have a computer in his home.[ By the time the tipping point had occurred in the early 1990s, it was too late for Digital Equipment Corporation, and its days of glory (and existence) were over. The story of Polaroid has a Digital Equipment Corporation déjà-vu flavor. Polaroid was a synonym for instant film. Several market research studies led Polaroid management to ignore the effect of digital cameras on its film business. By mid-2000s, it was essentially liquidated (but for the brand name).
Does Robotic Therapy Constitute a Disruptive Technology?
Capitalizing on the new understanding that the brain contains dynamic networks capable of remapping and creating new pathways after an injury, the authors introduced a paradigm shift in clinical practice in 1989 when they initiated the development of the Massachusetts Institute of Technology-Manus robot for neurorehabilitation 4 under the sponsorship of the National Science Foundation and, as defined by Christensen, offered a different package of attributes valued only in an emerging market of clinical visionaries remote from, and initially unimportant to, mainstream rehabilitation practices. Fletcher McDowell, MD, the former chief executive officer of the Burke Rehabilitation Hospital and Foundation, is one of these clinical visionaries in neurorehabilitation. After the National Science Foundation 5-yr sponsorship to develop the technology, he sponsored its deployment in the clinic in 1994 and nurtured it for the next 5 yrs until National Institutes of Health and Veterans Administration (VA) funds were secured to continue the research, and other groups around the country and world followed their footsteps. In what follows, the authors will argue that since 2010, the tipping point of robotic therapy (RT) was reached at least for the upper extremity (UE) RT, moving the field beyond clinical visionaries into the mainstream.
UE RT: The Tipping Point
Since the publication of the first controlled study with stroke inpatients, 5 several studies have been completed with both stroke inpatients and outpatients demonstrating the potential of RT for the UE. These results were discussed in different meta-analyses (see, e.g., Kwakkel et al. 6 ) and led to the 2010 American Heart Association guidelines for stroke care, which recommended that: BRobotassisted therapy offers the amount of motor practice needed to relearn motor skills with less therapist assistanceI Most trials of robot-assisted motor rehabilitation concern the upper extremity, with robotics for the lower extremity (LE) still in its infancyI Robot-assisted UE therapy, however, can improve motor function during the inpatient period after stroke.[ The American Heart Association suggested that robot-assisted therapy for the UE has already achieved Class I, Level of Evidence A for Stroke Care in the Outpatient Setting and Care in Chronic Care Settings. It suggested that robotassisted therapy for UE has achieved Class IIa, Level of Evidence A for stroke care in the inpatient setting. Class I is defined as BBenefit \ Risk. Procedure/ Treatment SHOULD be performed/administered[; Class IIa is defined as BBenefit d Risk, IT IS REA-SONABLE to perform procedure/administer treatment[; and Level A is defined as BMultiple populations evaluated: data derived from multiple randomized clinical trials or meta-analysis. [ 7 This is not an isolated opinion. The 2010 VA/ Department of Defense (DOD) guidelines for stroke care came to the same conclusion endorsing the use of rehabilitation robots for the UE but went further to recommend against the use of robotics for the lower extremity (LE). More specifically, the VA/DOD 2010 guidelines for stroke care BRecommend robotassisted movement therapy as an adjunct to conventional therapy in patients with deficits in arm function to improve motor skill at the joints trained.[ For the LE, the VA/DOD states that BThere is no sufficient evidence supporting use of robotic devices during gait training in patients post stroke.[ The VA/DOD issued a recommendation to use robotassisted therapy for the UE: BA recommendation that clinicians provide (the service) to eligible patients. At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm.[ Regarding the LE, the VA/DOD suggested against robot-assisted therapy: BRecommendation is made against routinely providing the intervention to asymptomatic patients. At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits. [ 8 Subsequent to the publication of the American Heart Association and VA/DOD guidelines, the results of the largest single study of robotics have become available: the multisite, independently run, Veterans Affairs trial CSP-558 (VA-ROBOTICS) on chronic stroke of UE rehabilitation robotics using the commercial version of the Massachusetts Institute of Technology-Manus for shoulder-andelbow therapy together with the corresponding antigravity, wrist, and hand robots. 9 VA-ROBOTICS included 127 Veterans with chronic stroke at least 6 mos post-index stroke with an impairment level characterized as very severe to moderate (Fugl-Meyer Assessment between 7 and 38 of 66 points for the UE). Veterans with multiple strokes were included in this study, which lasted for 36 wks: a 12-wk intervention followed by a followup period lasting 6 mos. Veterans were randomly assigned to either the RT group (n = 49), the intensitymatched comparison (ICT) group (n = 50), or the usual care (UC) group (n = 28). VA-ROBOTICS compared the efficacy of robot-mediated therapy (RT) with that of UC and ICT. UC was not dictated or prescribed by the protocol. The treatment was allowed to vary as per therapy, targeting specifically the UE, which consisted of an average of three sessions per week from therapists delivering treatment as they deemed clinically appropriate for the UE. To encourage subject retention, subjects randomized to UC selected at trial completion their choice of an additional 12 wks of RT or ICT. The RT group received three sessions per week of robotic training for the shoulder-and-elbow, wrist, and hand that delivered 1024 movements per session. The ICT group received three sessions per week of a therapy created to have a therapist deliver comparable movement intensity and repetition as the RT group during the same period. Contrary to other studies of robotassisted rehabilitation that used a control intervention expected to have little effect on the primary outcome, VA-ROBOTICS is unique in that it included an active control treatment group. The study was based on the hypothesis that the RT group would experience greater improvement in motor impairment at 12 wks compared with the UC and ICT groups, as measured by the UE component of the Fugl-Meyer scale. Of note, the ICT intervention is not conventional therapy. It uses manual techniques but would likely be impractical to implement as clinical therapy. It is unlikely that therapists could consistently assist the paretic arm during standard clinical care for almost 1000 movements per session as done for the ICT group (instead of the typical 45 movements per session in UC for chronic stroke patients). 10 The authors created this control treatment specifically to compare the treatment effect of the robot providing assistance with these movements vs. a human therapist providing assistance with the same movements. 11 
RESULTS

Safety
VA-ROBOTICS evaluated the safety of the used rehabilitation robots. There were no serious adverse events in the RT group. A few patients mentioned muscle soreness, which is not surprising considering that they were making 1024 movements in an hourlong robot session with the paretic limb.
Clinical Outcomes
The first and perhaps most understated finding of the VA-ROBOTICS was that UC did not reduce impairment and disability or improve quality-of-life in chronic stroke survivors. It is important to note that one third of the UC group received ongoing conventional upper limb therapy for an average of three sessions per week. The UC intervention had no measurable impact, and to conserve financial resources, it was discontinued as futile midway through the study.
The comparison between the RT and UC groups included (1) the comparison between the RT group and UC subjects, which involved roughly only the first half of the RT group while the UC was not discontinued, and (2) whether the changes were robust and long lasting. On this score, robot therapy was statistically superior to UC in Stroke Impact Scale (quality-of-life) at the completion of the intervention and also in the Fugl-Meyer (impairment) and Wolf Motor Function (function) assessments 6 mos after the completion of the intervention.
The results are far more impressive if the whole RT group were compared with the UC group and not just the analysis that focused on the first half of the study. Although the results at 12 wks showed that the difference between the first half of the robotic treatment group and UC was greater than 2 Fugl-Meyer points, the difference between the second half of the RT group and UC group was almost 8 points in the Fugl-Meyer assessment, with the comparison of the total robotic group vs. the total UC showing a 5-point change (Fig. 1) .
The reason(s) for the smaller clinical effects of the robotic intervention in the first stage of the study when compared with the second stage of the study are debated. The authors contend that this discrepancy is most likely caused by the omission of a Bphase-in[ stage in this study. 12 When testing a new therapy, it is common practice to treat a predetermined number of subjects during the initial phase of the trial with the new therapy at each site before beginning data collection for the actual controlled trial to gain familiarity and expertise with the novel treatment. This hypothesized learning effect for therapists supervising RT is perhaps worthy of further study, as some might have expected RT to be operator independent. Nevertheless VA-ROBOTICS demonstrates the robustness of the results: even when therapists are learning how to use the novel tools, the results are better than those of UC.
The comparison between the RT and ICT groups did not show any differences. 11 That said, the study biostatisticians selected the most conservative approach to deal with the data. They used a fixed model instead of a mixed model to estimate the 36 wks' outcome. They estimated a single model using data from all the patients in the study (UC, RT, and ICT) and then used this model to estimate the outcomes at follow-up for each intervention. Because the interventions are different, the authors argue that it may be appropriate to use a less conservative approach and use mixed models. Figure 2 illustrates the impact of fixed model on the data. A direct measurement at 36 wks demonstrates that the RT leads to an advantage of approximately 2 points in the Fugl-Meyer assessment. However, using a fixed model depressed the measurement of the RT group at 36 wks and pumped up that of the ICT group. This leads to an estimate of j0.58 favoring the ICT over the RT group in Fugl-Meyer assessment. However, none of these differences were significant.
Note also that patients in the RT group continued to improve even after the intervention was completed at 12 wks. Thus, the continued and persistent improvement at the 6-mo follow-up evaluation suggests improved robustness and perhaps an incremental advantage that prompted further improvement even without intervention. For example, an improvement of roughly 3 points in the Fugl-Meyer scale might enable a very severe patient to start to raise his/her arm and to bathe independently or to start to stretch the formerly paralyzed arm so that independent dressing could take place. It might enable a more moderate stroke patient to start to tuck in the shirt or to hike the pants independently or to start to reach overhead and actively grasp an object.
This continued improvement after completion of the intervention is quite remarkable because VA-ROBOTICS included patients with chronic stroke disability in the moderate to severe range and more than 30% had multiple strokes. As such, the group represented a spectrum of disability burden that many studies have avoided and, in this study, represented most cases. Note that 65% of the volunteers interviewed were enrolled. It suggests that RT for the UE offers an opportunity to a broad spectrum of stroke patients.
Cost Outcomes
In this era of cost containment, an important and unexpected result arose from the recently completed cost-benefit analysis. 13 The purchase cost of the four robotic modules (shoulder-elbow, wrist, antigravity, and hand) was $230,750; the interest rate on borrowing to purchase these robots was estimated at 6.015%, with 33% facility overhead on top of the purchase value and a $5,000 annual maintenance fee per robot. However, the additional cost of delivering RT or ICT was $5152 and $7382, respectively, and the difference was statistically significant (P G 0.001). Although the active interventions (RT and ICT) added cost, when the total cost, which includes the clinical care needed to take care of these veterans for the 36 wks of the trial (12 wks of intervention and 6 mos without any active intervention), was compared, there were no differences between active intervention and UC. The total cost for the VA was roughly the same: $17,831 for robot therapy, $19,746 for intensive comparison, and $19,098 for the UC. The UC group used the rest of the healthcare system more often than did the active intervention groups. In other words, for 36 wks of care, the robotic group cost the VA $5,152 for RT and $12,679 for clinical care. For 36 wks of care, the UC group cost the VA approximately $19,098.
The authors initially speculated that, perhaps, the surprising decreases in healthcare cost were caused by a Hawthorne effect. The active groups were receiving extra attention during the 36 wks of trial duration. To determine whether that was the case, the VA health economists (Palo Alto VA, Stanford University, CA) continued to collect cost data on these patients. One may speculate that if placebo accounted for a significant component of these cost reductions, then costs should trickle up after trial completion. On the contrary, they did not for the RT group. The healthcare cost until the end of September 2009 (after the 36 wks of the trial) averaged $7,777 for the RT group and $14,513 for the ICT group; this difference was statistically significant (P G 0.04).
One needs to take these results with the appropriate caveatsVthe sample size was small and predominantly male and had severe to moderate strokes, the data variability was large; nevertheless, the results suggest better care for the same total cost.
LE RT: in Its Infancy
The two most common LE robotic rehabilitation devices are the Lokomat (Hocoma, Zurich, Switzerland) and the Autoambulator (Healthsouth/ Motorika, Israel). The estimates are that there are already around 350 Lokomats and around 100 Autoambulators in clinical settings, yet the negative perception of LE robotic rehabilitation is not without merit. Although the installed robotic base is reasonably large, there are few published randomized controlled studies supporting their use. In fact, some of the large studies using the Lokomat (Hocoma) showed statistically significantly inferior results when compared with those produced by UC as practiced in the United States for both chronic as well as for subacute stroke patients. 14, 15 Of course, the characteristics and intensity of UC might vary according to the country, and hence, it is important to acknowledge that these results comparing Lokomat training with UC are primarily valid for the United States. However, it is appropriate to note that Healthsouth, who first developed and has used the largest numbers of Autoambulators for almost 10 yrs, has not published any controlled studies on that device, and the VA, which uses the largest number of Lokomats, has recently published a guideline recommending against its use post-stroke by its clinicians. 8 Figure 3 shows the outcomes of two studies comparing LE rehabilitation robotics with UC. The top row shows results with chronic stroke patients (stroke onset 9 6 mos), who trained three times per week for 30 mins for 4 wks, demonstrating improvements for the Lokomat-trained (white bars) and the UC (black bars) groups. However, the UC group improved significantly more than the Lokomattrained group. Of note, the same inferior results were observed for all levels of impairment; that is, both severe and moderate strokes seem to benefit more from UC than Lokomat training. For subacute stroke patients (stroke onset G6 mos) who trained for 8 wks, a qualitatively similar result was observed. Both groups improved from admission to midpoint, to completion, and to a 3-mo follow-up, but patients in the UC group improved more, and the difference between groups was statistically significant.
There are many plausible reasons for these results and the apparent immaturity of LE RT. The authors would like to highlight that, perhaps, a better understanding of the difference between Bbest practices[ and tested practices is needed. Clinicians and technologists assumed that body weightYsupported treadmill training delivered by two or three therapists was an effective and superior form of therapy compared with UC, and thus, automating body weightYsupported treadmill training seemed to be a logical approach. However, a National Institutes of HealthYsponsored randomized controlled study demonstrated that, contrary to the hypothesis of its clinical proponents, body weightY supported treadmill training administered by two or three therapists for 20 to 30 mins followed by 20 to 30 mins of overground carryover training did not lead to superior results when compared with a home program of strength training and balance ([Locomotor Experience Applies Post-Stroke] Study). 16 These are landmark results that must be seriously acknowledged by both roboticists and clinicians: the goal of rehabilitation robotics is to optimize care and augment the potential of individual recovery, not to automate current rehabilitation practices, which for the most part, lack a scientific evidential basis, primarily because of the lack of tools to properly assess the practices themselves. 17 
Defining Success in Robotic Rehabilitation
The benchmark required to determine whether a disruptive technology has gone beyond a different package of attributes valued only in emerging markets into the mainstream must be defined. Mainstream rehabilitation services require not only advanced technology but also compelling features that will encourage therapy providers to use them. What is compelling to therapy providers, however, may not be equally important to patients, clinical managers, clinical physicians, therapists, or payors. Therefore, one must pay heed to all features so that all perspectives and users will be accommodated.
To satisfy all perspectives and users without generating too much controversy, the authors believe that the success of a therapeutic neurorehabilitation can be defined by positive answers to all of the following benchmarks:
Does the therapy help? Does the therapy help more than Busual[ standard of care? Does the therapy help more than Busual[ standard of care at the same or lower cost? OR if higher cost, does it present a positive costbenefit ratio? Take the example of VA-ROBOTICS: the researchers compared three sets of chronic stroke patients receiving UE RT, an ICT group, and an UC group in the VA system.
Although the RT and ICT groups improved, the UC group did not satisfy the first criterion: it did not lead to any measurable improvement.
The RT and ICT groups also satisfied the second criterion: the RC and ICT groups improved more than the UC group did.
When these groups were benchmarked against each other in terms of cost, RT for the UE was considerably cheaper than the ICT, and it led to slightly lower overall healthcare cost (intervention plus all the healthcare utilization costs) than both the UC and the ICT did, thereby satisfying the third benchmark (thought not to be a significant difference).
In view of these three positive answers to the benchmarks, one can argue that UE interactive robotic rehabilitation looks very promising, and the authors suggest that the VA-ROBOTICS represents the tipping point favoring RT and moving it into mainstream rehabilitation services.
In contrast, the same conclusion cannot be reached for the LE, as evidenced by the results obtained by Hornby et al. 14 and Hidler et al. 15 when using the Lokomat to deliver therapy for chronic and subacute stroke patients.
The robotic Lokomat group led to improvements in both chronic and subacute stroke patients satisfying the first benchmark. However, it failed to satisfy the second benchmark: compared with UC as practiced in the United States, it led to inferior results. Accordingly, it would be premature to benchmark it against the third criterion. 17 
